Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Company Info
SIC2836
Composite FIGIBBG008P7F869
CIK0001714899
IPODec 8, 2017
Sectorbiological products, (no diagnostic substances)
The chart shows the growth of an initial investment of $10,000 in Denali Therapeutics Inc. Common Stock, comparing it to the performance of the S&P 500 index. All prices have been adjusted for splits and dividends.
Returns By Period
Denali Therapeutics Inc. Common Stock (DNLI) has returned 23.95% so far this year and 83.56% over the past 12 months. Looking at the last ten years, DNLI has achieved an annualized return of -0.43%, underperforming the Benchmark (SPY), which averaged 12.23% per year.
DNLI
1M3.61%
6M34.09%
YTD23.95%
1Y83.56%
5Y-17.11%
10Y-0.43%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Denali Therapeutics Inc. Common Stock (DNLI) with color gradation from worst to best to easily spot seasonal factors.
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2026
30.49%
-0.70%
-9.18%
5.57%
2025
12.40%
-26.24%
-16.90%
22.52%
-19.90%
5.27%
-4.55%
12.03%
-3.20%
10.82%
21.84%
-13.56%
2024
-24.20%
22.40%
2.65%
-24.76%
19.51%
22.79%
5.91%
2.69%
19.58%
-11.03%
-6.19%
-18.41%
2023
7.65%
-10.10%
-15.04%
8.47%
21.61%
-2.35%
-3.13%
-18.41%
-11.42%
-8.28%
-1.59%
16.76%
2022
-23.17%
-6.14%
0.34%
-26.81%
2.84%
20.91%
15.13%
-18.35%
11.28%
-8.40%
7.91%
-12.88%
2021
-18.69%
3.49%
-20.20%
4.68%
5.60%
23.53%
-34.75%
3.54%
-6.68%
-4.52%
-4.06%
-4.52%
2020
31.89%
-15.80%
-12.93%
28.97%
29.62%
-10.81%
-2.82%
34.54%
12.85%
15.25%
42.85%
36.00%
2019
-6.48%
13.81%
5.59%
4.80%
-22.20%
8.52%
1.38%
-16.24%
-14.70%
2.62%
12.88%
-2.63%
2018
45.38%
-1.84%
-14.32%
-6.00%
4.28%
-21.43%
-16.18%
55.79%
12.76%
-32.26%
19.81%
7.77%
2017
-27.42%
Performance Indicators
The charts below present risk-adjusted performance metrics for Denali Therapeutics Inc. Common Stock (DNLI) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of DNLI compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Denali Therapeutics Inc. Common Stock volatility is 4.72%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses. Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
2025
2023
2022
2021
2020
2019
2018
Liabilities And Equity (USD)
1.14B
1.15B
1.46B
1.40B
1.60B
553.23M
661.98M
Equity Attributable To Parent (USD)
1.01B
1.03B
1.04B
962.29M
1.15B
394.89M
546.85M
Equity Attributable To Noncontrolling Interest (USD)
The regenerative medicine market, projected to reach $578 billion by 2033, faces a critical manufacturing challenge in scaling cell and gene therapies. Several companies are addressing this bottleneck through different approaches: Prime Medicine with prime editing technology, Madrigal Pharmaceuticals with sustained therapeutic results, Iovance Biotherapeutics with FDA-approved TIL therapy, Denali Therapeutics with protein engineering, and Avaí Bio with a Master Cell Bank for encapsulated cell products that enable off-the-shelf manufacturing.
Benzinga•Usa News Group
AI Insight
Advancing tividenofusp alfa with multiple regulatory designations and an April 2026 PDUFA target date, demonstrating progress in scaled biomanufacturing.
Denali Therapeutics announced clinical progress across three lysosomal storage disorder programs using its proprietary Enzyme TransportVehicle platform. Tividenofusp alfa (DNL310) for Hunter syndrome showed sustained biomarker reductions and clinical improvements through Week 201, with an FDA PDUFA decision expected April 5, 2026. DNL126 for Sanfilippo syndrome type A demonstrated an 80% mean reduction in cerebrospinal fluid heparan sulfate in preliminary Phase 1/2 data. DNL952 for Pompe disease entered Phase 1 testing with preclinical data showing improved glycogen reduction in muscle and brain.
GlobeNewswire Inc.•Denali Therapeutics Inc.
AI Insight
Company demonstrated significant clinical progress across multiple programs with sustained biomarker reductions, FDA Priority Review for lead candidate with April 2026 decision date, FDA alignment on surrogate endpoint for accelerated approval pathway, and expansion into new disease areas. Safety profiles consistent with established therapies support advancement toward commercialization.
Denali Therapeutics announced it will present clinical and preclinical data from its Enzyme TransportVehicle (ETV) programs at the 2026 WORLDSymposium in February. The company will showcase continued Phase 1/2 data for tividenofusp alfa (DNL310) for Hunter syndrome, which is under FDA Priority Review with a decision expected by April 5, 2026, as well as preliminary data from DNL126 for Sanfilippo syndrome type A and Phase 1 study design for DNL952 for Pompe disease.
GlobeNewswire Inc.•
AI Insight
The company is advancing multiple clinical programs with data presentations at a major symposium, has FDA Priority Review for its lead candidate with an expected decision in April 2026, and is preparing for commercial launch. The presentation of positive clinical data and continued progress across three disease programs demonstrates advancement in their TransportVehicle platform technology.
Denali Therapeutics announced publication of Phase 1/2 trial results for tividenofusp alfa (DNL310), an investigational enzyme replacement therapy for Hunter syndrome (MPS II) that crosses the blood-brain barrier. The study showed significant reduction in key disease biomarkers, normalization of heparan sulfate levels in cerebrospinal fluid and urine, and improvements in clinical endpoints including cognition, adaptive behavior, and hearing. The FDA is conducting Priority Review of the Biologics License Application with a decision expected by April 5, 2026.
GlobeNewswire Inc.•Denali Therapeutics Inc.
AI Insight
Publication of Phase 1/2 trial results in prestigious New England Journal of Medicine showing strong efficacy data with 91% reduction in cerebrospinal fluid heparan sulfate levels, 93% of participants reaching normal levels, and clinical improvements in cognition and hearing. FDA Priority Review with expected decision by April 2026 represents significant regulatory progress. Multiple FDA designations (Breakthrough Therapy, Rare Pediatric Disease, Fast Track, Orphan Drug) support advancement toward potential approval.
Denali Therapeutics plans to raise approximately $200 million through a public offering of 9,142,857 common stock shares and pre-funded warrants at $17.50 per share, with underwriters including Goldman Sachs, J.P. Morgan, Morgan Stanley, and Jefferies.
GlobeNewswire Inc.•Denali Therapeutics Inc.
AI Insight
The company is raising capital through a standard public offering, which indicates a strategic financial move to fund operations without significant positive or negative implications
Denali Therapeutics appointed Tim Van Hauwermeiren to its Board of Directors and announced the departure of Chief Medical Officer Carole Ho to Eli Lilly, with Peter Chin assuming the Acting Chief Medical Officer role.
GlobeNewswire Inc.•Denali Therapeutics Inc.
AI Insight
Routine leadership transition with internal promotion and strategic board addition
The global Sandhoff disease treatment market is projected to grow from $260 million in 2024 to $456.42 million by 2034, with a 5.75% CAGR. North America dominates the market, and gene therapy is expected to be a key growth segment for treating this rare genetic disorder.
GlobeNewswire Inc.•Towards Healthcare
AI Insight
Dedicated to defeating neurodegenerative and lysosomal storage diseases through rigorous therapeutic discovery and development
Denali Therapeutics has initiated a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II). The company also has positive ongoing interactions with the FDA on the development of DNL126 for Sanfilippo syndrome type A (MPS IIIA) through the START program.
GlobeNewswire Inc.•
AI Insight
The article highlights Denali's progress in the development of tividenofusp alfa for Hunter syndrome, including the initiation of a BLA filing for accelerated approval, as well as the positive ongoing interactions with the FDA on the development of DNL126 for Sanfilippo syndrome. This suggests the company is making advancements in its pipeline and collaborating effectively with regulatory authorities.
The mucopolysaccharidosis market is witnessing a surge in innovation, driven by cutting-edge gene therapies, enzyme replacement treatments, and novel drug developments. The market is poised for exponential growth with rising awareness, early diagnosis, and increasing investments in rare disease research.
GlobeNewswire Inc.•Delveinsight
AI Insight
Denali Therapeutics is developing DNL126, an investigational enzyme replacement therapy for the potential treatment of MPS IIIA (Sanfilippo syndrome type A), showcasing the company's involvement in the MPS III market.
The article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical trials.
GlobeNewswire Inc.•Delveinsight
AI Insight
Denali Therapeutics Inc is highlighted as one of the companies evaluating new alpha-synuclein inhibitor drugs, suggesting their involvement in the development of this class of therapies.
